🚀 VC round data is live in beta, check it out!
Medicenna Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Medicenna Therapeutics and similar public comparables like Evaxion, Passage Bio, FibroGen, Pluri and more.
Medicenna Therapeutics Overview
About Medicenna Therapeutics
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL-13 Superkines and Empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. Its pipeline candidates include MDNA11 for Cancer immunotherapies, MDNA55 is a Molecular Trojan Horse, and BiSKITs represent a novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
Founded
2015
HQ
Employees
23
Website
Sectors
Financials (LTM)
EV
$29M
Medicenna Therapeutics Financials
Medicenna Therapeutics reported last 12-month revenue of $32K.
In the same LTM period, Medicenna Therapeutics generated had net loss of ($15M).
Revenue (LTM)
Medicenna Therapeutics P&L
In the most recent fiscal year, Medicenna Therapeutics reported revenue of — and EBITDA of ($15M).
Medicenna Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $32K | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($15M) | XXX | XXX | XXX |
| EBIT Margin | (52720%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($15M) | XXX | ($9M) | XXX | XXX | XXX |
| Net Margin | (46185%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Medicenna Therapeutics Stock Performance
Medicenna Therapeutics has current market cap of $37M, and enterprise value of $29M.
Market Cap Evolution
Medicenna Therapeutics' stock price is $0.45.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $29M | $37M | 1.9% | XXX | XXX | XXX | $-0.10 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMedicenna Therapeutics Valuation Multiples
Medicenna Therapeutics trades at 912.4x EV/Revenue multiple, and (2.0x) EV/EBITDA.
EV / Revenue (LTM)
Medicenna Therapeutics Financial Valuation Multiples
As of April 18, 2026, Medicenna Therapeutics has market cap of $37M and EV of $29M.
Equity research analysts estimate Medicenna Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Medicenna Therapeutics has a P/E ratio of (2.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $37M | XXX | $37M | XXX | XXX | XXX |
| EV (current) | $29M | XXX | $29M | XXX | XXX | XXX |
| EV/Revenue | 912.4x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.0x) | XXX | XXX | XXX |
| EV/EBIT | (1.7x) | XXX | (2.0x) | XXX | XXX | XXX |
| P/E | (2.5x) | XXX | (4.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (2.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Medicenna Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Medicenna Therapeutics Margins & Growth Rates
Medicenna Therapeutics' revenue in the last 12 month grew by 3003%.
Medicenna Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.6M for the same period.
Medicenna Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3003% | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 2% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 13892% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 39036% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Medicenna Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Medicenna Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Evaxion | XXX | XXX | XXX | XXX | XXX | XXX |
| Passage Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| FibroGen | XXX | XXX | XXX | XXX | XXX | XXX |
| Pluri | XXX | XXX | XXX | XXX | XXX | XXX |
| NextCure | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medicenna Therapeutics M&A Activity
Medicenna Therapeutics acquired XXX companies to date.
Last acquisition by Medicenna Therapeutics was on XXXXXXXX, XXXXX. Medicenna Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Medicenna Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMedicenna Therapeutics Investment Activity
Medicenna Therapeutics invested in XXX companies to date.
Medicenna Therapeutics made its latest investment on XXXXXXXX, XXXXX. Medicenna Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Medicenna Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Medicenna Therapeutics
| When was Medicenna Therapeutics founded? | Medicenna Therapeutics was founded in 2015. |
| Where is Medicenna Therapeutics headquartered? | Medicenna Therapeutics is headquartered in Canada. |
| How many employees does Medicenna Therapeutics have? | As of today, Medicenna Therapeutics has over 23 employees. |
| Who is the CEO of Medicenna Therapeutics? | Medicenna Therapeutics' CEO is Fahar Merchant. |
| Is Medicenna Therapeutics publicly listed? | Yes, Medicenna Therapeutics is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Medicenna Therapeutics? | Medicenna Therapeutics trades under MDNA ticker. |
| When did Medicenna Therapeutics go public? | Medicenna Therapeutics went public in 2017. |
| Who are competitors of Medicenna Therapeutics? | Medicenna Therapeutics main competitors are Evaxion, Passage Bio, FibroGen, Pluri. |
| What is the current market cap of Medicenna Therapeutics? | Medicenna Therapeutics' current market cap is $37M. |
| What is the current revenue of Medicenna Therapeutics? | Medicenna Therapeutics' last 12 months revenue is $32K. |
| What is the current revenue growth of Medicenna Therapeutics? | Medicenna Therapeutics revenue growth (NTM/LTM) is 3003%. |
| What is the current EV/Revenue multiple of Medicenna Therapeutics? | Current revenue multiple of Medicenna Therapeutics is 912.4x. |
| Is Medicenna Therapeutics profitable? | No, Medicenna Therapeutics is not profitable. |
| What is the current net income of Medicenna Therapeutics? | Medicenna Therapeutics' last 12 months net income is ($15M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.